180 related articles for article (PubMed ID: 1373535)
1. Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients.
Sakr M; Hassanein T; Gavaler J; Abu-Elmagd K; Fung J; Gordon R; Starzl T; Van Thiel D
Transplantation; 1992 Apr; 53(4):786-91. PubMed ID: 1373535
[TBL] [Abstract][Full Text] [Related]
2. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience.
Neuhaus P; Blumhardt G; Bechstein WO; Platz KP; Jonas S; Mueller AR; Langrehr JM; Lohmann R; Schattenfroh N; Knoop M
Transplantation; 1995 Jan; 59(1):31-40. PubMed ID: 7530868
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group.
Pirsch JD
Transplantation; 1999 Oct; 68(8):1203-5. PubMed ID: 10551653
[TBL] [Abstract][Full Text] [Related]
4. Management of acute steroid-resistant rejection after liver transplantation.
Platz KP; Mueller AR; Zytowski M; Lemmens P; Lobeck H; Neuhaus P
World J Surg; 1996 Oct; 20(8):1052-8; discussion 1058-9. PubMed ID: 8798364
[TBL] [Abstract][Full Text] [Related]
5. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression.
Hadley S; Samore MH; Lewis WD; Jenkins RL; Karchmer AW; Hammer SM
Transplantation; 1995 Mar; 59(6):851-9. PubMed ID: 7535482
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation.
Griffith BP; Bando K; Hardesty RL; Armitage JM; Keenan RJ; Pham SM; Paradis IL; Yousem SA; Komatsu K; Konishi H
Transplantation; 1994 Mar; 57(6):848-51. PubMed ID: 7512292
[TBL] [Abstract][Full Text] [Related]
7. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
[TBL] [Abstract][Full Text] [Related]
8. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.
Hibberd PL; Tolkoff-Rubin NE; Cosimi AB; Schooley RT; Isaacson D; Doran M; Delvecchio A; Delmonico FL; Auchincloss H; Rubin RH
Transplantation; 1992 Jan; 53(1):68-72. PubMed ID: 1310173
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppression impact on long-term cardiovascular complications after liver transplantation.
Rabkin JM; Corless CL; Rosen HR; Olyaei AJ
Am J Surg; 2002 May; 183(5):595-9. PubMed ID: 12034401
[TBL] [Abstract][Full Text] [Related]
10. Non-lymphoid cancer after liver transplantation.
Frezza EE; Fung JJ; van Thiel DH
Hepatogastroenterology; 1997; 44(16):1172-81. PubMed ID: 9261620
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
12. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
[TBL] [Abstract][Full Text] [Related]
13. Use of FK 506 in pancreas transplantation.
Gruessner RW; Sutherland DE; Drangstveit MB; Troppmann C; Gruessner AC
Transpl Int; 1996; 9 Suppl 1():S251-7. PubMed ID: 8959841
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
Cao S; Cox KL; Berquist W; Hayashi M; Concepcion W; Hammes GB; Ojogho OK; So SK; Frerker M; Castillo RO; Monge H; Esquivel CO
Pediatr Transplant; 1999 Feb; 3(1):22-6. PubMed ID: 10359027
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients.
Kim SJ; Lee KW; Lee DS; Lee HH; Lee SK; Kim B; Huh WS; Oh HY; Joh JW
Transplant Proc; 2004 Sep; 36(7):2098-100. PubMed ID: 15518759
[TBL] [Abstract][Full Text] [Related]
16. Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation.
Steinebrunner N; Sandig C; Sommerer C; Hinz U; Giese T; Stremmel W; Zahn A
Transpl Infect Dis; 2014 Jun; 16(3):379-86. PubMed ID: 24666466
[TBL] [Abstract][Full Text] [Related]
17. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation.
Porayko MK; Textor SC; Krom RA; Hay JE; Gores GJ; Richards TM; Crotty PH; Beaver SJ; Steers JL; Wiesner RH
Mayo Clin Proc; 1994 Feb; 69(2):105-11. PubMed ID: 7508536
[TBL] [Abstract][Full Text] [Related]
18. OKT3 prophylaxis in liver transplantation.
McDiarmid SV; Millis MJ; Terasaki PI; Ament ME; Busuttil RW
Dig Dis Sci; 1991 Oct; 36(10):1418-26. PubMed ID: 1833167
[TBL] [Abstract][Full Text] [Related]
19. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients.
Platz KP; Mueller AR; Blumhardt G; Bachmann S; Bechstein WO; Kahl A; Neuhaus P
Transpl Int; 1994; 7 Suppl 1():S52-7. PubMed ID: 11271297
[TBL] [Abstract][Full Text] [Related]
20. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial.
McDiarmid SV; Busuttil RW; Ascher NL; Burdick J; D'Alessandro AM; Esquivel C; Kalayoglu M; Klein AS; Marsh JW; Miller CM
Transplantation; 1995 Feb; 59(4):530-6. PubMed ID: 7533345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
